Backgrounds: Stereotactic ablative radiotherapy (SABR) is one of the newly developed innovative radiotherapy and of which optimal dose prescription needs to be standardized. We aimed to investigate the dose-response relationship for patients with SABR. Methods: Fifty-three patients with Stage I non-small cell lung cancer patients, who underwent SABR between November 2006 and January 2015, were evaluated retrospectively. Thirteen patients (24.5%), who refused the surgery were included and 40 patients (75.5%) were medically inoperable at diagnosis. The median age was 74 years. The median SABR dose was 50 Gy in 3-8 fractions and the median biologically effective dose (BED;α/β = 10) was 105.6 Gy (range: 60-160.53 Gy). Results: The median follow-up was 37.1 months. The 1 and 3 year local control rates were 91.7% and 85.1%. The 3 year overall and progression-free survival rate were 63.3% and 47.5%, respectively, and freedom from progression was 62.2%. Local control rate and 3-year overall survival according to tumor size was 100% and 79.4% in T1 tumors in a while 61.8% and 45% in T2a tumors. The 3-year local and regional control by BED 10 was 79.4% and 69.4% in ≤100 Gy vs. 89.1% and 100% in >100 Gy (P = 0.526, 0.004). Dyspnea more than Grade 3 was reported in six (11.3%) patients and Grade 1 chest pain was shown in five (9.4%) patients. Conclusions: The excellent regional control was conferred with a prescription of more than BED 10 of 100 Gy, which also might be needed to achieve better local tumor control in T2a patients with tolerable lung function.
Introduction
Lung cancer is the most common cause of cancer-related death in both men and women, and disease management is crucial at the time of an initial diagnosis (1) . Historically, surgical treatment such as lobectomy has been considered as the first treatment modality for early stage lung cancer, but the increase in the elderly patient population has made it further difficult to apply surgery to all patients (2) . With the development of precise radiotherapy and imaging technologies, stereotactic ablative radiotherapy (SABR) has been taking the role of surgery in those elderly or medically inoperable patients with comorbidities as the series of studies have reported the treatment outcomes comparable to those from surgery (3, 4) . A propensity score matching study and a pooled analysis of two randomized trials showed no significant difference in overall survival (OS) outcomes between SABR and surgery, even in operable early stage lung cancer (5) (6) (7) . Recently, the American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of SABR in early stage non-small cell lung cancer (NSCLC) (8) . However, the dose prescription was variable throughout institutions and the optimal dose prescription has not yet been determined. In Japanese multi-institutional dose escalation study for SABR reported that a radiation dose of more than biologically effective dose (BED) of 100 Gy (α/β = 10 for tumors) conferred better local control rates and longer survival in early stage NSCLC patients (9) . For T2 lesions, multicenter retrospective analysis reported that treated with BED 10 > 105 Gy, better local control was observed. (10) In addition, RTOG 0236 and a single institutional studies showed that escalation of BED 10 more than 150 Gy to planning target volume (PTV) in T2 tumors could achieve better tumor control (11, 12) . Considering the variety of target delineation and dose prescription in performing SABR throughout institutions, we need to search the optimal way of delivering SABR in their own institutions (13) .
In this study, throughout assessing the tumor control and failure pattern of Stage I NSCLC patients with SABR, we aimed to find any dose correlation (BED 10 ) with these outcomes.
Patients and methods

Patient eligibility
Fifty-three Stage I NSCLC patients who underwent SABR at Chonnam National University Hwasun Hospital from November 2006 to January 2015 were evaluated retrospectively. Disease was pathologically confirmed in all except two patients. This study was approved by the institutional review board (IRB) of the hospital and IRB granted a waiver for individual patient consent for this retrospective review. Our inclusion criteria for this analysis were tumor size less than 5 cm, and peripheral tumor location (2 cm or more away from the bronchial tree). Patients with pathologically confirmed hilar and/or mediastinal lymph node metastasis or radiologically positive lymph nodes were excluded from the analysis. The Eastern cooperative group (ECOG) performance status (PS) was used to evaluate the general condition of each patient. The maximum diameter of the gross tumor was based on the longest part of the tumor with a lung window level on radiation planning CT. Lung cancer tumor board defined patients as medically inoperable based on age, lung function (baseline forced expiratory volume 1 (FEV1) ≤40%, and predicted or diffusing capacity for carbon monoxide (DLCO) ≤50%) and ECOG PS ≥ 2. Patients with significant comorbidities (chronic renal failure, cardiovascular disease, etc.) were also classified as medically inoperable.
Treatment characteristics
For obtaining CT data, each patient's body was immobilized, with both arms elevated above the head in vacuum devices. Respiratorycorrelated four-dimensional CT (4DCT) data was acquired using a BrightSpeed CT scanner (GE Medical Systems, Milwaukee, WI, USA) and an RPM gating system (Varian, Palo Alto, CA, USA). Total 10-phase CT data were reconstructed retrospectively and the internal target volume (ITV) was created in the 50%-phase CT. The PTV was created with a setup margin of 5-8 mm from ITV. The SABR plans were delivered with a RPM gating method irradiating only in 10-20% of the full respiratory period, corresponding with the stable region of end exhalation. The SABR plans were made using the intensity modulated radiosurgery (IMRS) technique. The IMRS plans were created using an Eclipse planning system (Varian, Palo Alto, CA, USA) with seven fixed gantry angle beams, and the anisotropic analytic algorithm (AAA) was applied in the dose calculation for lung inhomogeneity correction. A clinical linear accelerator, Clinac iX (Varian, Palo Alto, CA, USA), and a 6 MV photon beam were used in this study. A total dose of 40-54 Gy at the PTV in 3-8 fractions was prescribed. Dose constraints to the normal adjacent organs were based on the guidelines used in Radiation Therapy Oncology Group (RTOG) SABR trials (14, 15) . The SABR was performed on consecutive weekdays with a median treatment duration of 5 days (range: 3-14 days). All patients underwent onboard cone-beam computed tomography (CBCT), which performed 3D verification of the tumor position on a daily basis, immediately before treatment. We applied the biologically effective dose (BED 10 ) concept of the linear quadratic model, total dose × (1 + dose per fraction/[α/β;10 Gy for lung carcinoma]). With this formula, we compare the total treatment dose in each fractionation schedule.
Outcome and survival analysis
Patients were followed-up 4-6 weeks after treatment, subsequently every 3-4 months for up to 2 years, and thereafter every 6 months for up to 5 years. We defined local progression as a size increase of the maximum tumor diameter >20% (RECIST ver. 1.1) (16) . In cases with controversy differentiating recurrence and radiation changes, additional 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) was performed, or serial changes in tumor size and density were followed for at least 6 months to determine local progression. Regional recurrence was defined as relapse in the ipsilateral hilar lymph node, or both mediastinal lymph nodes, and any recurrences beyond aforementioned areas were defined as distant metastasis. Toxicity assessment was performed through Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Respiratory symptoms (e.g. dyspnea) and treatment related pain (e.g. chest pain including rib fracture) after SABR treatment were thoroughly evaluated.
Statistical analysis
The Kaplan-Meier method and the log-rank test were used to compare local and regional recurrence, distant metastasis and survival outcomes in patients to determine the differences between groups. The Cox proportional hazards model was used for multivariate analysis, and SPSS 22.0 software (SPSS, Chicago, USA) was used for statistical analysis. In this study, we classified P value less than 0.05 as statistically significant. Hazard ratio and 95% confidence interval were shown through Cox proportional hazards model.
Results
Patient and tumor characteristics are described in Table 1 . The patient age ranged from 54 to 87 years (median: 74 years) and the male to female ratio was 40:13. The ECOG performance status (PS) score was 0 in 16, 1 in 29, 2 in 6, and 3 in 2 patients. Twenty patients (37.7%) presented with a maximum tumor diameter of more than 3 cm. Tumor histology was squamous cell carcinoma in 24 patients (47.1%), adenocarcinoma in 22 patients (43.1%), and other histological types in five patients (9.8%). Thirteen patients (24.5%), who refused the surgery were included and 40 patients (75.5%) were medically inoperable.
Total radiation doses and fractionation schedules were prescribed based on each patient's reserved lung function and tumor size ( Table 2 ). The median SABR dose was 50 Gy to PTV in 3-8 fractions, and the median BED 10 was 105.6 Gy (α/β = 10; range: 60-160.53 Gy). Thirty-two patients (60.4%) were treated with more than BED 10 of 100 Gy. According to tumor size, 78.8% of T1 (26/33) and 30% of T2a (6/20) tumors were treated with more than BED 10 of 100 Gy.The median follow-up was 37.1 months (range: 2.3-100.3 months). The 1-and 3-year local control (LC) rates were 91.7% and 85.1%, respectively. The 3-year regional recurrence-free (RRF) and distant metastasisfree (DMF) rates were 87.7% and 73.1%, respectively. The 3-year freedom from progression (FFP) and progression-free survival (PFS) rates of all 53 patients were 65.1%, and 50%, respectively, and overall survival (OS) rate was 61.5% (Fig. 1 ).
Univariate and multivariate analysis
In univariate analysis, we evaluated possible prognostic parameters such as age, ECOG PS, tumor size, tumor location, tumor histology, medical operability, BED 10 regarding the local control, regional recurrence free and distant metastasis free status, freedom from progression and survival outcomes (Table 3) . Among all variables, tumor size showed the most statistical significance associated with survival outcomes and local control (Fig. 1) . Local control rate and 3-year OS according to tumor size was 100% and 79.4% in T1 tumors of ≤3 cm in a while 61.8% and 45% in T2a tumors more than 3 cm, respectively. Adenocarcinoma histology was significantly associated with poor PFS (P = 0.007) and marginally significant (P = 0.061) in OS. Neither local control nor any other survival outcomes were affected by medical operability of patient.
Relating to the cutoff dose of BED 10 100 Gy, LC rate was 89.1% in higher BED 10 group compared to 79.4% in lower BED 10 group without statistical significance (P = 0.526). However, BED 10 more than 100 Gy showed statistical significance in RRFS (P = 0.004) and marginal significance in FFP (P = 0.052), in a while PFS and OS were not affected by PTV BED 10 (Fig. 2) . We evaluated the relationship between the radiation dose and LC and survival outcomes according to the tumor size. In T1 tumors of ≤3 cm, 3-year LC between higher and lower BED 10 was 100% vs. 100% (P = 0.602) and 3-year OS was 71.4% vs. 72.5% (P = 0.535), respectively (Fig. 3) . In T2a tumors of >3 cm, the 3-year LC of higher BED 10 was 50.0% and lower BED 10 was 67.7% (P = 0.602) and 3-year OS was 33.3% vs. 50% (P = 0.287), respectively (Fig. 4) .
In multivariate analysis as shown in Table 4 , tumor size of >3 cm was the most statistically significant factor associated with poor outcomes in local control, distant metastasis, FFP, PFS and OS. Adenocarcinoma histology was also significantly associated with poor PFS and OS. 
Failure pattern and toxicities
We performed a detailed analysis of each recurrence pattern according to tumor size, histology and BED 10 ( Table 5) . Local progression was shown in eight (15%) patients and regional recurrence was shown in five (9%) patients. A total of 19 treatment failures occurred, of which 15 were distant metastases (78.9%, 15/19). Among three patients with local recurrence only, one patient was given SABR again, who died from intercurrent disease. For regional failure, mediastinal RT was done in three patients with good performance status (ECOG 0-1). Salvage chemotherapy was tried in five patients with distant metastasis. Only one patient with adenocarcinoma histology was given anti-EGFR target agent after chemotherapy. Toxicities associated with SABR (dyspnea and chest pain) were analyzed according to the medical operability (Table 6 ). Although lifethreatening toxicities were not encountered, dyspnea more than Grade 3 was reported in 6 (11.3%) patients and occurred only in the medically inoperable group. Grade 1 chest pain including rib fracture was shown in 5 (9.4%) patients (2 in operable vs. 3 in inoperable).
Discussion
In Stage I NSCLC, surgery is a good treatment option and provides excellent local tumor control and long-term survival. According to Japanese NSCLC surgical studies, 5-year OS was reported to bẽ 60-75% in Stage Ia, and 40-60% in Stage Ib (17, 18) . Yamamoto et al. reported that in NSCLC treated with video-assisted thoracic surgery (VATS) lobectomy, 5-year OS for Stage I was 85% for Ia, and 69% for Ib (19) . In recent years, SABR has been frequently adopted as an alternative treatment option in both operable and inoperable elderly patients with NSCLC. Verstegen et al. reported the results of propensity score matched analysis comparing the results of VATS lobectomy and SABR in Stage I-II NSCLC (7). Analysis of 1-and 3-year loco-regional control between the two groups revealed that SABR showed excellent efficacy (96.8% and 93.3% vs. 86.9% and 82.6%, respectively, P = 0.04), and also showed that there was no difference in OS among the two groups.
In this analysis, of all patients, 3-year local control rate was 85.1% and 3-year OS was 61.5%, which were seemed to be a rather disappointing comparing to the aforementioned results. The most significant prognostic factor in relation to tumor control and survival in our analysis was the tumor size (>3 cm, >2-≤3 cm and ≤2 cm), which was in consistent with previous studies (12, 20) . Local control rate and 3-year OS according to tumor size was 100% and 79.4% in cT1 tumors of ≤3 cm in a while 61.8% and 45% in T2a tumors more than 3 cm, respectively. We could confirm that SABR might replace the role of surgery safely in the management of cT1 tumors. However, in T2a tumors more than 3 cm, local control rate and OS was rather disappointing with our SABR techniques. In an effort to find the reasonable answers for this poor outcomes, we tried to find any dose-response correlation to the local control or survival. Onishi et al. have reported that local control and OS were improved with a BED 10 of over 100 Gy, and Grills et al. reported a 2-year local progression rate of 4-15% in T1-3N0M0 NSCLC receiving a BED 10 of 105 Gy (3, 21) . Several studies revealed that dose-response for a BED 10 was only seen in T2 lesions (10) (11) (12) . In this respect, we performed the analysis based on a PTV BED 10 of 100 Gy. Univariate analysis showed that BED 10 >100 Gy had a statistically significant effect on regional recurrence (P = 0.004) and marginal significance in FFP (P = 0.052). However, there was no significant difference in LC (P = 0.536), OS (P = 0.832) and PFS (P = 0.519) according to BED 10 and this indifference was maintained in the analysis incorporating of the tumor size. In our data, T2a tumors showed the tendency to be treated with lower BED 10. The regional recurrence rate varies from study to study, but a systematic review has reported a range of 0-23.4%, with a median of~10% (22) . In a study evaluating regional nodal relapse of Stage I/II NSCLC treated with SABR or hypofractionated radiotherapy, 10-15% of patients had a regional recurrence at hilar and/or mediastinum after RT (23) . In the present study, regional recurrences with or without distant metastasis occurred in five patients, accounting for 9.4% of all patients, which was comparable to the previously published results. In relation to the radiation dose, regional recurrence was not appeared in patients with higher BED 10 >100 Gy and only shown in patients with lower BED 10 . This might be explained with the hypothesis that higher doses of SBRT may result in low-dose spillage to regional nodes, which possibly eliminates microscopic disease (24) .
In this study, tumor board determined medical operability using pulmonary function parameters, ECOG PS score, and medical comorbidities, and 75.5% (40/53) of the patients were determined to be medically inoperable. The 3-year LC between the medically inoperable and operable groups showed no statistically significant difference (91.7% and 83.1% P = 0.433). Moreover, 3-year OS was similar between the two groups, with no statistically significant difference (61.5% and 61.7%, P = 0.880). The 3-year OS rate of medically inoperable patients in this study (61.7%) was comparable to those reported in other published studies (42.7-55.8%) (15, 25) .
In the evaluation of toxicities, Grade 3-4 dyspnea occurred in 11.3% (6/53) of all patients, which was similar with the toxicity profile reported by other studies. Baumann et al. reported 10.1% of Grade 3-4 side effects after a 45 Gy dose administered in three fractions, in patients with medically inoperable Stage I NSCLC (26) . A systemic review of toxicity profiles showed that a peripherally located tumor in inoperable patients, Grade 3 or higher toxicity (dyspnea, rib fracture, fibrosis or heart failure) was reported in 3-28% of cases (22) . Notably in this study, the dyspnea 3 or 4 was occurred only in medically inoperable patients with initially poor lung function. In the prospective multicenter study; JCOG0403, Nagata et al. also reported that Grade 3 and 4 toxicity occurred in 11(10.6%, 11/104) and 2(1.9%, 2/104) patients, especially in inoperable group (27) . We could understand that although, medical inoperability was not the barrier performing the SABR, but, should be cautious on the lung function changes and give an effort to reduce the lung damage after SABR. The limitations of this study were the variability in dose-fractionation, the retrospective study design, and the single institutional cohort. Local tumor control rates seemed to be lower than those reported by aforementioned studies. This might be because of the lower PTV BED 10 prescribed in T2a tumors, compared with those in other studies. We decreased the total radiation doses in larger PTV to reduce any SABR related toxicities that might occur in the situation of our own limited SABR experiences. PTV of T2a with lower BED 10 was median 70 cc (range: 60.2-95.8 cc). However, in patients who received more than 100 Gy PTV BED 10 , the regional recurrence and FFP rate of our analysis revealed efficacy comparable to those reported in previously published studies, validating the usefulness of SABR as a curative treatment option in clinical Stage I NSCLC. Future Phase III randomized controlled trials in peripheral Stage I NSCLC (SABRtooth, STABLE-MATES; NCT02468024) may further clarify whether SABR is comparable to surgery (28).
In conclusion, SABR could be safely delivered and survival outcomes were shown to be comparable to those resulting from surgery in tumor size of T1 NSCLC. A prescription of more than PTV BED 10 of 100 Gy might be needed to achieve better local and regional tumor control in T2a patients with tolerable lung function.
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